N-Ethylhexedrone

Heart disease, Hypertension, Arrhythmias, Structural heart abnormalities

NEH is a potent sympathomimetic that produces severe tachycardia (>160 bpm) and hypertension in clinical cases. Any pre-existing cardiovascular condition substantially increases the risk of cardiac arrhythmia, myocardial infarction, or stroke. Fatal cases document extreme cardiovascular stress as a primary mechanism of death.

Epilepsy, Seizure disorders

Synthetic cathinones reduce seizure threshold as a class effect. NEH's potent sympathomimetic action and documented hyperthermia (>41°C) compound this risk. Individuals with epilepsy or other seizure disorders face elevated risk of provoked seizures.

Schizophrenia, Schizoaffective disorder

Clinical case data document paranoia, feelings of persecution, and agitation during NEH intoxication. As a potent dopaminergic stimulant, NEH would exacerbate psychotic symptoms in individuals with pre-existing psychotic disorders.

Bipolar I, Bipolar II

Potent dopaminergic stimulants carry risk of triggering manic episodes in bipolar disorder. NEH's post-withdrawal depressive syndrome — documented in mice and observed clinically — represents additional risk for the depressive phase of bipolar cycling.

Major depressive disorder

Post-withdrawal depression-like behavior specific to NEH has been documented in mice (not seen with buphedrone) and clinical observations report anhedonia, abulia, and psychomotor slowing during recovery. Individuals with MDD face heightened vulnerability to post-use depressive exacerbation.

Generalized anxiety disorder, Panic disorder

Anxiety and paranoia are documented in clinical NEH intoxication cases. The sympathomimetic cardiovascular effects (tachycardia, hypertension) can amplify somatic anxiety symptoms and trigger panic responses in vulnerable individuals.

Liver disease, Hepatic insufficiency

NEH is extensively metabolized by the liver through Phase I and Phase II pathways. Hepatic impairment would reduce metabolic clearance, prolonging the already extended elimination half-life (19–28 hours) and increasing risk of drug accumulation and toxicity.

Kidney disease, Chronic kidney disease

Acute kidney failure was documented in the monosubstance-dominant fatal case. NEH's prolonged elimination half-life (19–28 hours) means impaired renal function would further extend systemic exposure and increase nephrotoxic risk.

Hyponatremia, Electrolyte imbalance

Syndrome of inappropriate antidiuretic hormone secretion (SIADH) was documented in one monosubstance NEH intoxication case, noted by the authors as a potentially underrecognized complication. Individuals with pre-existing hyponatremia or conditions predisposing to electrolyte imbalance face elevated risk.

Pregnancy

As a potent sympathomimetic with documented hyperthermia exceeding 41°C, NEH use during pregnancy carries presumed risk to fetal development including potential vasoconstriction of placental blood supply and teratogenic hyperthermia. No reproductive toxicity studies have been conducted.

MAOI use

Combining NEH with monoamine oxidase inhibitors creates risk of hypertensive crisis and potentially serotonin syndrome. NEH's inhibition of norepinephrine reuptake combined with MAOI-mediated blockade of monoamine catabolism produces dangerously elevated synaptic catecholamine concentrations.

Hyperthyroidism

Hyperthyroidism produces a state of adrenergic excess. NEH's sympathomimetic cardiovascular stimulation would compound this, increasing risk of tachycardia, arrhythmia, and hyperthermia.

Pheochromocytoma

Pheochromocytoma causes episodic catecholamine release. NEH blocks catecholamine reuptake at DAT and NET, which would dangerously potentiate endogenous catecholamine surges, risking severe hypertensive crisis and cardiac events.